The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

tele.md

Stage

Seed VC | Alive

Total Raised

$180K

Last Raised

$180K | 5 yrs ago

About TeleMD

TeleMD uses artificial intelligence (AI) for cancer diagnostics and prognostication.

TeleMD Headquarter Location

Presnenskaya nab., 10

Moscow,

Russian Federation

+7 495 649-13-09

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing TeleMD

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

TeleMD is included in 6 Expert Collections, including Artificial Intelligence.

A

Artificial Intelligence

8,693 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

M

Medical Devices

7,910 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

D

Digital Health

12,788 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

7,900 items

Latest TeleMD News

Artificial intelligence for medical diagnostics gets VC backing

Aug 3, 2017

3 Aug '17 Primer Capital, a Russian VC fund focused on biomed, has invested more than $180,000 in a software platform by TeleMD, a domestic start-up that uses artificial intelligence (AI) for cancer diagnostics and prognostication, Firrma reported . The start-up is reported to have plans to use the money to fine-tune the platform’s image recognition functionality for cancer diagnostics, and also to make the solution scalable for medical specialists from across disciplines to be able to analyze heterogeneous medical data. Sergei Sorokin, the TeleMD project leader, is hoping his platform will soon be marketed as “both a cloud-based solution and a self-contained software product.” TeleMD is designed to enable physicians to diagnose and predict oncologic developments in complicated cases by analyzing medical images and other patient-specific data. With the solution, doctors may expect to be able to reach out to broader medical communities and get remote advice. TeleMD is reported to have developed its diagnostics criteria and algorithms in close collaboration with experts from the Moscow-based Russian Blokhin Research Center for Oncology and some other leading scientific hubs and clinical centers. Primer Capital has a notably long history of backing advanced biomed projects. Last year alone, for example, the VC fund supported TsSB Genomics, a genomics solutions developer, FK Laboratories developing anti-thrombosis drugs, and a range of other start-ups. COMMENT ON THIS STORY

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.